BRPI1014505A2 - métodos e composições para tratar e previnir infecção por escherichia coli produtora de toxina shiga. - Google Patents

métodos e composições para tratar e previnir infecção por escherichia coli produtora de toxina shiga.

Info

Publication number
BRPI1014505A2
BRPI1014505A2 BRPI1014505A BRPI1014505A BRPI1014505A2 BR PI1014505 A2 BRPI1014505 A2 BR PI1014505A2 BR PI1014505 A BRPI1014505 A BR PI1014505A BR PI1014505 A BRPI1014505 A BR PI1014505A BR PI1014505 A2 BRPI1014505 A2 BR PI1014505A2
Authority
BR
Brazil
Prior art keywords
compositions
treating
methods
escherichia coli
shiga toxin
Prior art date
Application number
BRPI1014505A
Other languages
English (en)
Inventor
Andrew A Porter
David Asper
Dragan Rogan
Original Assignee
Bioniche Life Sciences Inc
Univ Saskatchewan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioniche Life Sciences Inc, Univ Saskatchewan filed Critical Bioniche Life Sciences Inc
Publication of BRPI1014505A2 publication Critical patent/BRPI1014505A2/pt
Publication of BRPI1014505A8 publication Critical patent/BRPI1014505A8/pt
Publication of BRPI1014505B1 publication Critical patent/BRPI1014505B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • C07K16/1232—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI1014505A 2009-04-06 2010-04-06 Proteína de fusão de múltiplos epítopos, método para produzir uma composição, polinucleotídeo, vetor recombinante, célula hospedeira, método para produzir umaproteína de fusão de múltiplos epítopos, kit de teste imunodiagnóstico, composição, e, uso de uma proteína de fusão de múltiplos epítopos BRPI1014505B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21198909P 2009-04-06 2009-04-06
US21660809P 2009-05-19 2009-05-19
PCT/CA2010/000516 WO2010115278A1 (en) 2009-04-06 2010-04-06 Methods and compositions for treating and preventing shiga toxin-producing escherichia coli infection

Publications (3)

Publication Number Publication Date
BRPI1014505A2 true BRPI1014505A2 (pt) 2016-04-05
BRPI1014505A8 BRPI1014505A8 (pt) 2017-07-11
BRPI1014505B1 BRPI1014505B1 (pt) 2020-02-04

Family

ID=42935602

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1014505A BRPI1014505B1 (pt) 2009-04-06 2010-04-06 Proteína de fusão de múltiplos epítopos, método para produzir uma composição, polinucleotídeo, vetor recombinante, célula hospedeira, método para produzir umaproteína de fusão de múltiplos epítopos, kit de teste imunodiagnóstico, composição, e, uso de uma proteína de fusão de múltiplos epítopos

Country Status (7)

Country Link
US (1) US8734811B2 (pt)
EP (1) EP2417165B1 (pt)
JP (2) JP2012522522A (pt)
AU (1) AU2010234193B2 (pt)
BR (1) BRPI1014505B1 (pt)
CA (1) CA2757828C (pt)
WO (1) WO2010115278A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2014001126A1 (es) * 2014-04-29 2014-08-29 Univ Chile Composición farmacéutica útil como vacuna contra bacterias escherichia coli productoras de shigatoxinas (stec), que comprende al menos un antígeno o una proteína de membrana externa inmunogénica o proteína inmunogénica asociada y conservada en cepas stec.
AU2020265755A1 (en) * 2019-05-01 2021-12-16 Innate Biologics Llc Immunomodulatory compositions and methods
EP4054655A4 (en) * 2019-11-08 2024-02-28 Ionis Pharmaceuticals, Inc. COMPOUNDS AND METHODS FOR REDUCING SPDEF EXPRESSION
WO2021242798A1 (en) * 2020-05-26 2021-12-02 Synlogic Operating Company, Inc. Surface display of proteins on recombinant bacteria and uses thereof
WO2024064200A2 (en) * 2022-09-20 2024-03-28 The Texas A&M University System Darpin-containing compositions and methods thereof
AR132724A1 (es) 2024-05-17 2025-07-23 Instituto Nac De Tecnologia Agropecuaria Inta Construcción de adn que codifica una proteína de fusión con al menos dos antígenos de escherichia coli enterohemorrágica, vectores, proteína de fusión, métodos de inmunización y vacunas

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055400A (en) 1986-11-26 1991-10-08 University Of Guelph Leukotoxin gene of pasteurella haemolytica
US4957739A (en) 1987-08-13 1990-09-18 Board Of Regents, The University Of Texas System Pharmaceutical compositions of a 105 kD P. Haemolytica derived antigen useful for treatment of Shipping Fever
CA2014033C (en) 1989-04-07 1993-02-09 Stephen D. Acres Compositions and treatments for pneumonia in animals
EP0527724B1 (en) * 1990-04-05 1997-08-27 The University of Saskatchewan Compositions and treatments for pneumonia in animals
US5238823A (en) 1990-08-22 1993-08-24 Veterinary Infectious Disease Organization Interleukin-2-leukotoxin gene fusions and uses thereof
US5273889A (en) 1990-08-22 1993-12-28 University Of Saskatchewan Gamma-iterferon-leukotoxin gene fusions and uses thereof
US5594107A (en) * 1990-08-22 1997-01-14 University Of Saskatchewan Chimeric protein comprising an RTX-family cytotoxin and interferon-2 or interferon
AU2699192A (en) 1991-10-16 1993-05-21 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
US5837268A (en) 1991-10-16 1998-11-17 University Of Saskatchewan GnRH-leukotoxin chimeras
US6797272B1 (en) 1991-10-16 2004-09-28 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
US5422110A (en) 1991-10-16 1995-06-06 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
US5723129A (en) 1991-10-16 1998-03-03 University Of Saskatchewan GnRH-leukotoxin chimeras
DK0904288T3 (da) 1996-04-23 2012-09-24 Univ British Columbia Patogent Escherichia coli-associeret protein
PT1029054E (pt) 1997-11-12 2009-11-11 Univ British Columbia Hp90: receptor membranar do hospedeiro para bactérias patogénicas codificado pelo gene bacteriano tir
NZ509137A (en) * 1998-06-04 2004-01-30 Metamorphix Internat Inc Methods for reducing GnRH levels in prepubertal vertebrates as an alternative to surgical sterilisation
US6365723B1 (en) 1998-12-04 2002-04-02 Wisconsin Alumni Research Foundation Sequences of E. coli O157
WO2002053181A1 (en) * 2001-01-04 2002-07-11 University Of Saskatchewan Enterohemorragic escherichia coli vaccine
WO2004050119A1 (en) * 2002-11-29 2004-06-17 Imperial College Innovations Limited Vaccine against enteropathogenic and enterohaemorragic escherichia coli
WO2007101337A1 (en) 2006-03-06 2007-09-13 Bioniche Life Sciences Inc. Methods and compositions comprising bacterial type hi secreted proteins for mucosal immunization of animals
CA2646319A1 (en) * 2006-04-20 2007-11-01 The Henry M. Jackson Foundation For The Advancement Of Military Medicine , Incorporated Methods and compositions based on shiga toxin type 1 protein

Also Published As

Publication number Publication date
JP2016029049A (ja) 2016-03-03
BRPI1014505A8 (pt) 2017-07-11
CA2757828C (en) 2019-01-08
US8734811B2 (en) 2014-05-27
BRPI1014505B1 (pt) 2020-02-04
AU2010234193A1 (en) 2011-11-03
EP2417165A1 (en) 2012-02-15
EP2417165A4 (en) 2013-02-13
EP2417165B1 (en) 2016-05-25
JP2012522522A (ja) 2012-09-27
AU2010234193B2 (en) 2015-08-20
WO2010115278A1 (en) 2010-10-14
WO2010115278A8 (en) 2010-12-02
CA2757828A1 (en) 2010-10-14
US20120087939A1 (en) 2012-04-12

Similar Documents

Publication Publication Date Title
BRPI1007379A2 (pt) composições e métodos para o tratamento ou a prevenção de infecções orais por e. coli
PH12016502092A1 (en) Antimicrobial compounds and methods of making and using the same
BRPI1009920A2 (pt) composições bacterianas para profilaxina e tratamento de doença degenerativa.
BRPI0815057A2 (pt) Composto, composição farmacêutica, e, método para tratar infecção.
WO2011047323A3 (en) Antimicrobial compounds and methods of making and using the same
BRPI0815283A2 (pt) Equipamento para o tratamento da biomassa, método para o tratamento da biomassa, biomassa tratada e hidrolisado
BRPI1007477A2 (pt) método, e, composição de tratamento de poço
BRPI0911757A2 (pt) composiÇÕes e mÉtodos para tratar distérbios digestivos.
BRPI0818732A2 (pt) Composições de análogo de prostaglandina e métodos para tratar condições relacionadas epiteliais.
BRPI1006145A2 (pt) "composição e método para tratamento de diabetes".
BRPI1007929A2 (pt) "métodos e composições para o tratamento de neovascularização".
PH12015502375B1 (en) Antimicrobial compounds and methods of making and using the same
BR112012006671A2 (pt) composição antimicrobiana sinérgica, e, método para inibir o crescimento microbiano
BRPI1016257A2 (pt) composições compreendendo finafloxacino e métodos para tratar infecções oftálmicas, ópticas ou nasais
DOP2010000373A (es) Derivados de urea heterociclicos para el tratamiento de infecciones bacterianas
BRPI1014505A2 (pt) métodos e composições para tratar e previnir infecção por escherichia coli produtora de toxina shiga.
BR112012004676A2 (pt) método de tratar infecções orotomixovirais.
HRP20141270T1 (xx) Detoksificirani imunogeni escherichie coli
BRPI0916885A2 (pt) composição farmacêutica, e, método para tratar uma infecção bacteriana
BRPI0910514A2 (pt) bactérias recombinantes para produção de deoxiviolaceína e seus usos.
BRPI0910620A2 (pt) método de tratamento de plantas cítricas para redução de infecção bacteriana
MY165011A (en) Antimicrobial compounds and methods of making and using the same
BRPI0808823A2 (pt) composição e método para tratar, reduzir, melhorar ou prevenir uma infecção.
BRPI0822905A2 (pt) Método para o tratamento de produtos, e, câmara climática.
PL2134742T3 (pl) Kompozycje immunogenne do leczenia i profilaktyki zakażeń zwierząt

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: UNIVERSITY OF SASKATCHEWAN (CA) , TELESTA THERAPEUTICS INC. (CA)

Owner name: UNIVERSITY OF SASKATCHEWAN (CA) , TELESTA THERAPEU

B25A Requested transfer of rights approved

Owner name: UNIVERSITY OF SASKATCHEWAN (CA)

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/04/2010, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2822 DE 04-02-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.